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A R T I C L E   I N F O A B S T R A C T 
Inhalation therapies are central to the management of chronic obstructive 
pulmonary disease (COPD). Although, findings from previous studies reveal 
suboptimal use and a wide range of problems with inhaler handling among COPD 
patients, very little is known about how and why problems arise. A systematic 
search of studies related to the topic area was conducted using Scopus and PubMed, 
from 2000 to 2013. As a result, twenty-two studies were included. Most studies had 
similar baseline characteristics. This review indicated that adherence to inhalation 
therapy was of concern. Rates of non-adherence to medication ranged from 29.5% to 
80%. This review confirms non-adherence as a problem among patients and 
identifies factors which were potential contributors to medication non-adherence. 
The review reveals issues in operating the inhalation devices especially with the 
pressurised metered dose inhalers (pMDIs), which may lead to sub-optimal 
therapeutic outcomes and treatment failures.  
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INTRODUCTION 
Global prevalence and burden of COPD 
Chronic obstructive pulmonary disease (COPD) is a 
long term condition characterised by progressive 
narrowing of the airways and premature ageing of 
the lungs. As reported by the Quality and Outcomes 
Framework (QOF) (DH 2010), in England in 2008, 
15.4 million people had a long-term condition, 
including COPD which was the third most common 
after coronary heart disease and diabetes. By 2020, 
COPD is estimated to be the third biggest cause of 
death in the UK, after heart disease and stroke 
(Mannino 2006; BLF 2008). In addition to what stated 
earlier, chronic obstructive pulmonary disease 
(COPD) imposes a large financial burden on health 
services and is among the most costly diseases in the 
UK (DH, 2011). 
What are the inhalation therapies available for the 
management of CODP? 
Inhalation therapies are central to the management 
of COPD. They include both oral and inhaled 
medications (e.g. bronchodilators, corticosteroids 
and combination therapies) and are delivered by 
pressurised metered dose inhalers (pMDIs), dry 
powder inhalers (DPIs), and nebulisers (NICE 2010). 
Why review the use of medication among COPD 
patients? 
Different terms were used in the scientific literature 
to describe patients’ medication use one of which is 
adherence and compliance. These terms are used 
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interchangeably, despite being different in the 
meaning which should be noted. Compliance is 
defined as ʺthe extent to which a person’s behaviour 
(in terms of taking medications, following diets, or 
executing lifestyle changes) coincides with medical 
or health adviceʺ (WHO, 2008). The term adherence is 
defined similarly, but implies active participant 
involvement. Therefore, the term adherence was 
used throughout this review.  
Medication non-adherence has been identified as a 
major public health problem that imposes a 
considerable financial burden on healthcare services 
(Vermeire et al., 2001; Bender et al., 2014). This 
burden has been estimated worldwide to cost $100 
billion each year (Vermeire et al., 2001). In 2010, the 
cost of COPD was projected to be approximately 
US$50 billion, which includes $20 billion in indirect 
costs and $30 billion in direct health care 
expenditures. These costs can be expected to 
continue to rise with this progressive disease 
(Guarascio et al., 2013). The WHO estimates that the 
average non-adherence rate is 50% among those with 
chronic illnesses including COPD (Chisholm-Burns 
and Spivey, 2003). Strategies to improve adherence to 
inhalation therapy among patients (e.g. patient 
instruction and education) have been shown to work 
among patients with asthma (Put et al., 2003; 
Onyirimba et al., 2003), whereas, in COPD patients, 
these strategies were less successful (Rand, 2005; 
Restrepo, et al., 2008). Therefore, non-adherence 
remains an unresolved problem despite decades of 
research, and is a factor resulting in suboptimal 
clinical outcomes and poor disease control.  
Why review the use of devices among COPD users? 
The review of the literature reveals that incorrect use 
of inhalation devices in regards to the inhalation 
techniques which means that little or no medicine 
reaches the lungs, is very common among patients 
with COPD, leading to suboptimal drug delivery. 
Therefore, users may receive lower benefits from 
their treatment, which may result in the prescription 
of unnecessarily high doses and higher healthcare 
costs. It has been estimated that $5 to $7 billion in the 
United States is wasted every year because of inhaler 
misuse (Fink and Rubin, 2005). The review of the 
literature reveals suboptimal use and a wide range of 
problems with inhaler handling. However, very little 
is known about how and why problems arise and 
what practical issues COPD patients faced when 
using inhalation devices in combination. 
What are the objectives of this review? 
The objectives were, firstly, to establish the extent to 
which COPD patients’ medication use regarding 
adherence to inhalation therapy has been studied 
and review evidence regarding adherence rates and 
how COPD patients made decisions about the use of 
these medications; and, secondly, to identify all 
research evidence relevant to problems patients had 
with inhalation devices in the preparation and 
operation of inhaler equipment aiming to identify 
behaviours which may lead to treatment failures or 
exacerbations. 
MATERIALS AND METHODS 
Search strategy 
The electronic databases Scopus and PubMed were 
searched using the following MeSH terms: [Chronic 
Obstructive Pulmonary Disease OR COPD OR 
Chronic Obstructive Airway Disease OR Chronic 
Obstructive Lung Disease OR Airflow Obstruction 
Chronic OR Chronic Airflow Obstructions] AND 
[Drug Therapy] AND [Medication Adherence OR 
Medication Compliance OR Medication Use] AND 
[Inhalation Technique]. Searches were restricted to 
English language and human studies and limited by 
the period from 2000 to 2013, as this period witnessed 
the introduction of many therapeutic agents and 
higher technological devices for inhalation therapy, 
especially with the introduction of the patient-
friendly devices DPIs. Additionally, there was a 
systematic review published in 2001 by Brocklebank, 
covering almost similar aspects of this review by 
comparing the medication use and effectiveness in 
asthma and chronic obstructive airways disease. 
Therefore, it was decided to take this review further 
to find out how COPD patients and their behaviours 
have changed with regard to their use of their 
medicines or devices since that review (Brocklebank 
et al., 2001). The reference lists of all included articles 
and identified reviews were also manually searched 
to identify any other relevant studies. 
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Study selection 
The criteria for relevant studies were: (1) patients 
with COPD aged over 18 years old because COPD 
mainly affects middle-aged or older adults who 
usually smoke; using inhalation devices; in primary 
care; (2) studies reported in the English language. 
Eligible studies were peer-reviewed studies. Studies 
that examined the timing, dosage, frequency of 
medication and inhalation technique were included. 
Articles referring to adherence to oxygen therapy, 
pulmonary rehabilitation and exercise were 
excluded. Articles examining medication adherence 
for other pulmonary diseases such as asthma were 
excluded. This criterion was applied given that 
COPD is a progressive disease, and that treatments 
for COPD differ markedly compared to other 
respiratory diseases (Rand, 2005). However, studies 
that examined COPD together with other diseases 
were included. Whilst, intervention studies which 
have not covered or assessed patients’ adherence 
during or after the intercession were also excluded 
because it was not part of this study objectives. 
Data extraction and quality assessment 
Electronic databases were searched and duplicate 
articles were removed. All articles were reviewed 
manually by title, abstract and/or full-text for 
relevance. The reference lists of retrieved articles 
were manually examined for further applicable 
studies. Full text manuscripts were retrieved either 
electronically or as hard copy for assessment (see 
Figure 1). Information was extracted into a proforma 
which included: primary author name and date of 
publication, country of the study, study settings, 
sample, methods employed, measures used and 
results. The characteristics of the studies of 
medication use of multiple inhalation therapy and 
the practical aspects of operation of the inhalation 
devices studies among COPD patients are reported 
Table 1 and Table 2 respectively. 
RESULTS AND DISCUSSION 
Search results and study characteristics 
The initial search yielded 123 results with an 
additional thirteen studies identified through 
manual searches of reference lists. After removing 9 
duplicates, 127 unique papers were retained and 
assessed against eligibility criteria. Of these, 22 
studies have met criteria for inclusion in the review. 
Of the 22 studies, 11 studies examined patients’ 
medication use regarding adherence (Table 1). 
Eleven studies examined the aspects of operation of 
inhalation devices and described the frequency and 
range of problems experienced by COPD patients 
when using their inhalation devices (Table 2). 
These studies were mostly based in outpatient clinics 
(N=11) (Lenney et al., 2000; Hesselink et al., 2001; 
George et al., 2005; Khassawneh et al., 2008; De 
Moraes Souza et al., 2009; Rootmensen et al., 2010; 
Melani et al., 2011; Agh et al., 2011 ; Cecere et al., 
2012; Huetsch et al., 2012; Khdour et al., 2012), and 
patients’ home (N=5) (Melani et al., 2001; Barta et al., 
2002; Boyter and Carter, 2005; George et al., 2006; 
Sestini et al., 2006). Others were based in community 
pharmacies (N=3) (Hämmerlein et al., 2011; Mehuys 
et al., 2010; Trivedi et al., 2012).  
 
Fig. 1. Flow chart of study selection
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Table 1. Studies of medication non-adherence to COPD medicines worldwide. 
Study, Setting, 
Country 
Sample Definition of patients’ 
adherence/non 
adherence 
Methods/measures Study findings and conclusions 
Khdour (2012)  
Outpatient clinics, 
UK 
137 COPD 
patients 
Adherent: patients 
scoring 3 or above were 
classified as ‘adherent’. 
Cross sectional study 
Adherence to COPD medications was 
measured using patients’ self-reported 
questionnaire (4-items Morisky) 
Adherence was generally good. Rate of non-
adherence to COPD medications: 29.5% of the 
patients. 
Variables linked to medicine taking: A range of 
clinical and psychosocial variables such as 
perceived severity of the disease and benefits of 
medications. 
Cecere (2012) 
Outpatient clinics, 
USA 
167 COPD 
patients, 
prescribed LABA 
and  ICS 
Adherent: took 80% of 
doses as prescribed 
Clinical Randomised trial 
Adherence to COPD medicines was 
measured using prescription refill rates 
Adherence was generally poor. 
Rate of non-adherence to ICS: 60% of participants. 
Rate of non-adherence to LABA†: 46% of participants. 
Variables linked to medicine taking: patient 
perception of their provider as being an “expert” in 
diagnosing and managing lung disease. 
Huetsch (2012) 
Outpatient clinics, 
USA 
2,730 COPD 
patients, 
prescribed  
ICS,LABA, and IP 
Adherent: took 80% of 
doses as prescribed 
A cohort study  
Adherence to COPD medicines was 
measured using prescription refill rates 
Adherence was generally poor. 
Rate of non-adherence to ICS: 80.2% of participants. 
Rate of non-adherence to IP‡: 74.4% of participants. 
Rate of non-adherence to LABA†: 69.4% of 
participants. 
Variables linked to medicine taking highly variable 
and dependent on the medication being examined. 
Trivedi (2012) 
Outpatient clinics, 
USA 
374 COPD 
patients, 
prescribed LABA 
Adherent: took 80% of 
doses as prescribed 
Non-blinded cluster randomised clinical 
trial. 
Adherence to COPD medicines was 
measured using prescription refill rates 
Adherence was generally poor. 
Rate of non-adherence to LABA: 43% of participants. 
Variables linked to medicine taking: social care. 
Agh (2011) 
Outpatient clinics, 
Hungary 
170 participants 
with COPD 
Adherent: patients 
scoring 3 or above were 
classified as ‘adherent’. 
Cross-sectional observational study. 
Adherence to COPD medications was 
measured using patients’ self-reported 
questionnaire (4-items Morisky) 
Adherence was generally good. 
Rate of non-adherence to COPD medicines: 41.8 % of 
participants. 
Variables linked to medicine taking: age, smoking 
status, number of medicines, the number of daily 
doses and quality of life. 
Mehuys (2010) 
Community 
pharmacies 
Belgium 
555 patients with 
stable COPD 
No clear classification. Cross-sectional, observational study. 
Adherence to COPD medicines was 
measured using prescription refill rates. 
Adherence was generally poor. 
Rate of non-adherence to COPD medicines: 53% of 
participants. 
Variables linked to medicine taking: age and number 
of drugs. 
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Table 1. Continued…. 
Study, Setting, 
Country 
Sample Definition of patients’ 
adherence/non 
adherence 
Methods/measures Study findings and conclusions 
George (2006) 
Patients’ homes 
Australia. 
28 patients with 
moderate to 
severe COPD 
The identified themes 
for medication 
adherence were agreed 
among all the authors 
(pharmacists) 
Randomized controlled trial study. 
Factors associated with adherence to disease 
management interventions were explored 
using in depth semi-structured 
questionnaire. 
Adherence to disease management programs was 
found to be a complex process driven by 15 major 
themes such as personal beliefs and experiences 
which are related to patient, treatment, disease, and 
health professionals. 
George (2005) 
Ambulatory care, 
Australia 
276 patients with 
chronic lung 
diseases (90.6% 
with COPD, 5.4% 
with asthma, 2.2% 
bronchiectasis,and 
1.8% others) 
Highly adherent:  (a 
score of 25 indicates), 
while any other score 
reports suboptimal 
adherence. 
Cross-sectional descriptive study. 
Adherence was measured using patients’ 
self-reported questionnaire (the 
Medication Adherence Report Scale 
MARS).  
A 30-item Beliefs and Behaviour 
Questionnaire (BBQ) under three sections: 
beliefs, experiences, and behaviours were 
used to determine the factors that are 
related to medicine taking. 
Adherence was generally poor. 
Rate of non-adherence to COPD medicines: 60% of 
participants. 
Variables linked to medicine taking: patients’ beliefs, 
experiences, and behaviors with regards to both 
disease and treatment. 
Boyter (2005)  
Patients’ homes,  
The United 
Kingdom 
117 patients  
mainly with 
COPD, prescribed 
home nebuliser 
treatment 
Adherent: used home 
nebulizers at four times 
a day 
A survey study. 
Adherence to COPD nebulised medications, 
use and maintenance of equipments were 
measured and explored by patients’ self-
reported using anonymous postal 
questionnaire 
Adherence was generally poor. 
Rate of non-adherence to COPD medicines: 57% of 
participants. 
Barta (2002)  
Patients’ homes,  
The United 
Kingdom 
75 patients most 
with COPD, 
prescribed home 
nebuliser 
treatment 
Adherent: used home 
nebulizers at least once 
a day 
A survey study. 
Adherence to respiratory nebulised 
medications, use, technical issues, and 
concerns about side effects were measured 
and explored using patients’ self-reported 
anonymous postal questionnaire. 
Adherence was generally good. 
Rate of non-adherence to COPD medicines: 40% of 
participants. 
Variables linked to medicine taking: feeling worse, 
less confidence in treatment. 
Melani (2001)  
Patients’ homes, 
Italy 
1,257 COPD 
patients, 
prescribed home 
nebuliser 
treatment 
Adherent: used home 
nebulizers at least once 
a day 
Open, multicentre, cross-sectional, 
observational study. 
Adherence to respiratory nebulised 
medications, use, technical issues, and 
concerns about side effects were measured 
and explored using patients’ self-reported 
anonymous postal questionnaire. 
Adherence was generally poor. 
Rate of non-adherence to COPD medicines: 60% of 
participants. 
Variables linked to medicine taking: medication 
forgetfulness. 
ICS:  inhaled corticosteroids, COPD: Chronic Obstructive Pulmonary Disease, †LABA: long-acting beta-agonists, ‡IP: Ipratropium bromide 
 
  doi: 10.5920/bjpharm.2016.14 
Alhomoud (2016) Br J Pharm, 1, 30-45  35 
Table 2. Characteristics of studies of inhalation technique assessment among COPD patients worldwide. 
Study, 
Setting, 
Country 
Sample Developing 
check-lists 
Definition  of 
incorrect technique 
Kind of assessment Methods/measures Study findings and 
conclusions 
Hämmerlein 
(2011), 
Community 
pharmacies 
Germany 
757 patients with 
asthma or COPD 
using pMDIs and 
DPIs 
21-items checklist 
was developed to 
be used for all 
types of 
inhalation devices 
As a matter of 
principle, an error 
probability of less 
than 5% was 
demanded (P < 0.05), 
when using 
independent sample 
t-test 
 
Assessment was 
made based on a 
personal view of 
one rater. 
Multi-centre intervention study. 
Each single step was marked as 
been performed correctly or 
incorrectly. However, not all steps 
were relevant for each inhaler 
system, for example, shaking the 
inhaler in case of a DPI, non-
relevant steps should be marked as 
correct. 
Inhalation technique was 
judged insufficient in 80% of 
the patients. 
Melani (2011)  
Outpatient 
clinics, 
Italy 
1633 patients, most 
with COPD and 
asthma, using MDIs 
and DPIs 
Check-lists were 
adapted from   
previously 
published criteria 
by (Newman, 
2005) 
If one or more errors 
were made regarding 
these essential steps 
determined by 
(Newman, 2005) 
Assessment was 
made based on an 
agreement between 
multiple raters on 
set of criteria for the 
correct use. 
Cross-sectional, observational 
study. 
Assessment of inhalation technique 
was done using; a checklist that 
measures steps required for 
adequate drug delivery and 
categorized the steps into ‘essential’ 
and ‘non-essential’ errors and 
assessed only those ‘critical errors 
or essential steps’. 
Inhalation technique was 
judged insufficient among all 
DPIs users, ranging from 44% 
for Turbuhaler, 35% for Diskus 
and Handihaler. While, the 
inhalation technique among 
pMDIs users was generally 
good (12% of users made 
errors with the use). 
Patients committed more 
errors when using DPIs. 
Rootmensen 
(2010) 
Outpatient 
clinics, 
The 
Netherlands 
156 patients most 
with COPD and 
asthma, using MDIs 
and DPIs 
Check-lists 
adapted from 
published criteria 
(van der Palen, et 
al., 1995; van 
Beerendonk et al., 
1998). 
If one or more errors 
were made regarding 
these essential steps 
determined by (van 
der Palen, et al., 1995) 
Assessment was 
made on an 
agreement between 
3 raters on set of 
criteria for correct 
use with the 
assessment of the 
total inhalation 
technique. 
Randomized controlled trial. 
Assessment was done using 
checklists that measures steps 
required for adequate drug delivery 
and categorized the steps into 
‘essential’ and ‘non-essential’ and 
only those ‘critical errors or 
essential steps’ were measured. 
Inhalation technique was 
judged insufficient in 40% of 
the patients. 
Most errors were seen in 
demonstrations with pMDIs 
with or without spacer 
(respectively, 47 and 81%). 
Essential errors were recorded 
least in the prefilled Diskus 
(15%), Turbuhaler (18%), and 
Diskhaler (21%).  
Patients committed more 
errors when using pMDIs than 
when using DPIs. 
De Moraes 
Souza (2009) 
120 patients with 
COPD and asthma, 
using MDIs and DPIs 
Check-lists were 
adapted from   
previously 
No clear definition. Assessment was 
made based on a 
Observational study. 
Measuring the total inhalation 
technique for each inhaler 
Inhalation technique was 
judged insufficient in 94.2% of 
the patients. 
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Study, 
Setting, 
Country 
Sample Developing 
check-lists 
Definition  of 
incorrect technique 
Kind of assessment Methods/measures Study findings and 
conclusions 
Outpatient 
clinics, 
Brazil 
published criteria 
(Steier, et al., 2003; 
Molimard, et al., 
2003; Muchão, et 
al., 2008). 
personal view of 
one rater. 
individually. The quantity of errors 
committed by the asthma group 
patients and by the COPD group 
patients was compared for each 
device separately. 
Patients committed more 
errors when using pMDIs than 
when using DPIs. 
Khassawneh 
(2008) 
Outpatient 
clinics, 
Jordan 
500 patients with 
COPD using pMDIs 
and DPIs 
Not clearly listed If one or more errors 
were made regarding 
these essential steps, 
leading to indicating 
little or no delivery of 
the drug. 
No clear 
assessment.  
Cross-sectional observational study. 
Measuring steps required for 
adequate drug delivery and 
categorized the steps into ‘essential’ 
and ‘non-essential’. When one or 
more essential steps were made, 
inhalation technique was defined as 
incorrect. 
Among the DPIs, the 
Accuhaler device had the 
lowest rate of incorrect 
handling, when compared to 
Turbuhaler and Aerolizer. 
Patients committed more 
errors when using pMDIs than 
when using DPIs. 
Wilson (2007) 
Outpatient 
clinics, 
London,  
United 
Kingdom 
30 patients with 
COPD with evidence 
of airflow obstruction 
(*FEV1/FVC < 70%) 
and had no previous 
experience of DPIs 
Device-specific 
checklists were 
adapted from the 
package leaflet of 
each inhaler 
If one or more errors 
were made regarding 
these essential steps, 
leading to indicating 
little or no delivery of 
the drug. 
Assessment was 
made based on an 
agreement between 
two raters  on set of 
criteria for correct 
use 
Randomized controlled trial. 
Measuring steps required for 
adequate drug delivery and 
categorized the steps into ‘essential’ 
and ‘non-essential’. When one or 
more essential steps were made, 
inhalation technique was defined as 
incorrect. 
The numbers of perfect scores 
were not significantly different 
between devices, but the 
number of fatal errors that 
would result in no drug 
delivery was significantly 
more common in Aerolizer, 
and Handihaler. 
Sestini (2006) 
Outpatient 
clinics 
Italy. 
1,126 patients with 
COPD and asthma, 
using MDIs and DPIs 
Device-specific 
checklists were 
adapted from the 
package leaflet of 
each inhaler. 
A sum score was 
computed separately 
for each device, in 
which each item of 
the checklist 
considered as minor 
was scored as 1, and 
each one considered 
as major flaws 
received a score of 3. 
Assessment was 
made based on an 
agreement between 
two raters on set of 
criteria for correct 
use. 
An open, observational study. 
Measuring steps required for 
adequate drug delivery and 
categorized the steps as ‘minor’ and 
‘major’ errors and only those 
‘major’ errors were measured. 
When one or more major errors 
were made, inhalation technique 
was defined as incorrect. 
Inhaler misuse was common 
and similar for both pMDIs 
and DPIs. 
Ho (2004) 
Patients’ 
homes 
United 
Kingdom 
423 patients use 
MDIs, MDIs with a 
large volume spacer 
and bread actuated 
Check-lists 
adapted from 
previously 
published criteria 
(Connolly, 1995). 
Major errors were 
identified using 
previously published 
criteria (Connolly, 
1995). 
Assessment was 
made based on a 
personal view of 
one rater with the 
assessment of the 
total inhalation. 
Cross-sectional study. 
Measuring steps required for 
adequate drug delivery and 
categorized the steps into 
acceptable (perfect or minor errors 
not preventing adequate use of the 
Inhalation technique for breath 
actuated-inhalers was judged 
insufficient in 27.8% of the 
patients, compared to 17.9% of 
patients used p-MDIs alone 
and 2.9% with large volume 
spacers. 
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Study, 
Setting, 
Country 
Sample Developing 
check-lists 
Definition  of 
incorrect technique 
Kind of assessment Methods/measures Study findings and 
conclusions 
device) or unacceptable (major 
errors). 
Molimard 
(2003) 
Outpatient 
clinics, 
France 
3811 adult with 
COPD and asthma, 
using MDIs and DPIs 
Device-specific 
checklists were 
adapted from the 
package leaflet of 
each inhaler. 
If one or more errors 
were made regarding 
these essential steps, 
leading to indicating 
little or no delivery of 
the drug. 
Assessment was 
made based on an 
agreement between 
multiple raters on 
set of criteria for 
correct use. 
Randomized control clinical trial. 
Measuring steps required for 
adequate drug delivery and 
categorized the steps into ‘critical’ 
and ‘non-critical’ errors and only 
those ‘critical’ errors were 
measured. 
Inhalation technique judged 
insufficient in 49-55% of the 
patients use breath actuated 
devices compared to 76% used 
p-MDIs. 
11-12% of patients treated with 
Aerolizer, Autohaler, or 
Diskus made critical errors 
compared to 28% and 32% of 
patients treated with p-MDI 
and Turbuhaler, respectively. 
Hesselink  
(2001) 
Outpatient 
clinics 
The 
Netherland 
588 COPD and 
asthma patients using 
pMDIs and DPIs 
Using the short 
version, validated 
inhaler-specific 
checklist of 
the Dutch Asthma 
Foundation 
If one or more errors 
were made regarding 
these essential steps, 
leading to indicating 
little or no delivery of 
the drug. 
Unspecified Cross-sectional study. 
The checklist measures the 
adequacy of the most essential 
preparation and breathing 
manoeuvres necessary for optimal 
drug delivery. 
Inhalation technique was 
judged sufficient in 75.8% of 
the patients. 
Diskhaler device had the 
lowest rate of incorrect 
handling (4%), when 
compared to cyclohaler (11%) 
and Rotahaler/ Spinhalers 
(37%). 
Lenney (2000) 
Respiratory 
Function 
Laboratory 
United 
Kingdom 
100 patients with 
COPD using MDIs 
and DPIs 
Device-specific 
checklists were 
adapted from the 
package leaflet of 
each inhaler. 
If one or more errors 
were made regarding 
these essential steps, 
leading to indicating 
little or no delivery of 
the drug. 
Assessment was 
made based on an 
agreement between 
multiple raters on 
set of criteria for 
correct use. 
Cross-sectional observational study. 
Inhaler technique was graded in the 
following way; 
A. good technique indicating good 
delivery of the drug; 
B. poor technique indicating partial 
delivery of the drug; 
C. very poor technique indicating 
little or no delivery of the drug. 
Inhalation technique was 
judged sufficient in 91% of the 
patients using the breath-
actuated inhalers (Easi-Breathe 
and Autohaler), when 
compared to 79% of patients 
using pMDIs.   
COPD: Chronic Obstructive Pulmonary Disease, MDIs: Metered Dose Inhalers, DPIs: Dry Powder Inhalers 
*FEV1/ FVC: The ratio of forced expiratory volume in one second to forced vital capacity.
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Most of these studies were conducted in Europe, 
especially the UK (N=6) (Lenney et al., 2000; Barta et 
al., 2002; Ho et al., 2004; Boyter and Carter, 2005; 
Wilson et al., 2007; Khdour et al., 2012), followed by 
Italy (N=3) (Melani et al., 2001; Sestini et al., 2006; 
Melani et al., 2011), and the Netherlands (N=1) 
(Rootmensen et al., 2010),  Belgium (N=1) (Mehuys et 
al., 2010), Hungary (N=1) (Agh et al., 2011), France 
(N=1) (Hesselink et al., 2001), Germany (N=1) 
(Hämmerlein et al., 2011), the USA (N=3) (Cecere et 
al., 2012; Huetsch et al., 2012; Trivedi et al., 2012), 
Australia (N=2) (George et al., 2005; George et al., 
2006), Brazil (N=1) (De Moraes Souza et al., 2009) and 
Jordan (N=1) (Khassawneh et al., 2008). 
Study design and methods employed 
Most studies employed a cross-sectional study deign 
as the study participants were approached on one 
occasion (Lenney et al., 2000; Hesselink et al., 2001; 
Melani et al., 2001; Ho et al., 2004; George et al., 2005; 
Sestini et al., 2006; Khassawneh et al., 2008; De 
Moraes Souza et al., 2009; Mehuys et al., 2010; Agh et 
al., 2011; Hämmerlein et al., 2011; Melani et al., 2011; 
Huetsch et al., 2012; Khdour et al., 2012). Except for 
six studies which were conducted on a large national 
scale (Molimard et al., 2003; George et al., 2006; 
Wilson et al., 2007; Cecere et al., 2012; Rootmensen et 
al., 2010; Trivedi et al., 2012), and two were survey 
studies (Barta et al., 2002; Boyter and Carter, 2005). 
The sample size in these studies ranged from 28 to 
2,730 COPD patients (George et al., 2006; Huetsch et 
al., 2012). 
The majority of studies that has investigated 
medication use (adherence) among COPD patients 
have employed quantitative approaches (N=10) 
(Melani et al., 2001; Barta et al., 2002; Boyter and 
Carter, 2005; George et al., 2005; Mehuys et al., 2010; 
Agh et al., 2011; Cecere et al., 2012; Huetsch et al., 
2012; Khdour et al., 2012; Trivedi et al., 2012), by 
measuring the amount of medicine taken over a 
given time period. There is a paucity of qualitative 
studies (N=1) that have investigated patients’ 
medication use or adherence to their COPD 
medications; they have done so by considering 
variables such as adherence decisions which were 
influenced by patients’ beliefs about inhalation 
therapies and concerns of side effects (George et al., 
2006). The importance of a qualitative research is to 
illustrate the way people act and think. For example, 
how COPD patients use their medications and what 
their perceptions about these medication are and 
whether this affect their use. In addition, it explores 
patterns and barriers in people’s thoughts and 
behaviours. This sharply contrasts with quantitative 
research which only include numbers and statistical 
figures to test a hypothesis, or explaining 
phenomena. 
There are a number of ways to measure adherence 
among patients with COPD. Each method has its 
strengths and limitations. Most studies focused on 
assessing medication adherence using self-report 
questionnaires on medication utilisation (Melani et 
al., 2001; George et al., 2005; Agh et al., 2011; Khdour 
et al., 2012). The most commonly used self-report 
methods were Morisky Medication Adherence Scale 
(MMAS) (Agh et al., 2011; Khdour et al., 2012), and 
the Medication Adherence Rating Scale (MARS) 
(George et al., 2005), which are well-validated tools 
used widely for all chronic conditions including 
COPD. Using patient self-report method does not 
guarantee the accuracy of the result because some 
patients may want to please the healthcare 
professionals or the researchers by giving them 
incorrect information about medication use maybe 
deliberately or in-accidentally. Therefore, they may 
have introduced research bias. Self-report method 
when combined with other means of data collection 
such as a review of clinical records or medication 
count maybe more desirable for providing reliable 
findings by means of triangulation.  
Other studies used prescription refill rate by 
reference to pharmacy records of dispensed 
prescription or manual recording of collected 
prescriptions (Mehuys et al., 2010; Cecere et al., 2012; 
Huetsch et al., 2012; Trivedi et al., 2012). Two studies 
were by means of postal questionnaires (Barta et al., 
2002; Boyter and Carter, 2005), which were filled by 
patients. However, it cannot be ascertained whether 
the patient was the one who filled the survey. 
Although the use of postal questionnaires is very 
common in health and social research and findings 
can be generalizable to a wider population given that 
all other aspects of research such as sample size, 
randomisation, response rate, reliability and validity 
have been considered, this was rarely the studies 
described. 
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Findings of the studies  
Type of the used inhaled medication 
Bronchodilators were used more often than inhaled 
steroids in all reviewed studies on medication use 
(Barta et al., 2002 ; Boyter and Carter, 2005; Mehuys 
et al., 2010 ; Agh et al., 2011; Cecere et al., 2012; 
Huetsch et al., 2012 ; Khdour et al., 2012 ; Trivedi et 
al., 2012). Most frequently used bronchodilators were 
short-acting β2-agonists (SABA) and short-acting 
anticholinergic. Salbutamol was the most commonly 
used bronchodilator in these studies (Barta et al., 
2002; Boyter and Carter, 2005; Agh et al., 2011; 
Khdour et al., 2012; Huetsch et al., 2012). Whilst the 
least were ipratropium bromide (IP) (Barta et al., 
2002; Boyter and Carter, 2005; Huetsch et al., 2012), 
and theophylline (Mehuys et al., 2010; Agh et al., 
2011). In some studies combination drugs were used 
least often than single drugs (Mehuys et al., 2010; 
Cecere et al., 2012). Although, current trend include 
up to 3 combinations because a growing body of 
evidence suggests that triple therapy with an anti-
muscarinic agent, LABA and ICS is efficacious in the 
management of COPD, the majority of studies which 
were included in this review suggested that 
salbutamol/ipratropium bromide were the 
commonly used combination therapies by patients 
and are shown to be effective (Barta et al., 2002; 
Boyter and Carter, 2005). This drug mixture raises 
concerns about the safety and compatibility of 
different drug combinations. However, this physical 
and chemical incompatibility were not noted in any 
study which used combination therapies (Barta et al., 
2002; Boyter and Carter, 2005). 
Frequency of use and rates of non-adherence 
Inhalation therapy was used by patients in these 
studies on daily basis; which ranged from one to six 
times daily (Melani et al., 2001; George et al., 2006; 
Mehuys et al., 2010; Agh et al., 2011; Cecere et al., 
2012; Huetsch et al., 2012; Trivedi et al., 2012). 
However, intermittent or occasional use was 
described in few studies (George et al., 2005; Boyter 
and Carter, 2005; Mehuys et al., 2010; Cecere et al., 
2012; Huetsch et al., 2012; Trivedi et al., 2012), which 
could result in suboptimal adherence. Adherence 
among COPD patients has been found to be 
suboptimal in past studies, which ranged from 29.5% 
(Khdour et al., 2012) to 80% (Huetsch et al., 2012). 
However, caution must be taken before drawing 
conclusions due to the wide variation in the 
estimated rates of non-adherence reported in 
previous studies. As a result, treatment failures were 
a major concern for patients with COPD. However, 
this variation regarding the rate of non-adherence 
could be due to the differences in patient 
populations, definition of non-adherence, methods 
employed, disease status, or respiratory conditions 
included in each study, as some studies included a 
variety of lung diseases such as asthma, COPD and 
other lung conditions. 
Definition of non-adherence 
The most commonly used definitions of non-
adherence among patients with COPD in past 
studies were the following: three studies defined 
adherence to COPD medication as taking 80% of 
doses as prescribed (Cecere et al., 2012; Huetsch et al., 
2012; Trivedi et al., 2012). Another three studies used 
a method which was based on the definition used by 
previously validated questionnaires such as 4-item 
Morisky (patients scoring 3 or above were classified 
as ‘adherent’) (Agh et al., 2011; Khdour et al., 2012), 
or the MARS score (a score of 25 indicates perfect 
adherence) (George et al., 2005). 
Factors contributing to medication use among COPD 
patients 
The use of inhalation therapy in some studies was 
found to be dependent on the class of drug in three 
study (Cecere et al., 2012; Huetsch et al., 2012; Trivedi 
et al., 2012).  For example, adherence to long-acting 
bronchodilators and ICS was found to be suboptimal 
among previous studies (Cecere et al., 2012; Huetsch 
et al., 2012; Trivedi et al., 2012). This was justified by 
the prolonged efficacy provided by long-acting 
bronchodilators and ICS on the symptoms’ relief. 
Among the LABA and ICS users, it was found that 
participants adhered more to the LABA than ICS 
(Cecere et al., 2012; Huetsch et al., 2012; Trivedi et al., 
2012). However, the adherence was suboptimal for 
both classes among those with a low-adherence rate. 
The reason behind being more adherent to the LABA 
than the ICS is that some participants responded 
better and quicker to the LABA than the ICS and for 
this reason preferentially used the LABA, which 
provides superior relief. In addition, experiencing an 
actual side effect or fears of side effects with the use 
of ICS was greater among participants who used 
different classes. In a recent study conducted by 
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Davis et al.’s (2016) to evaluate health care costs and 
utilization among COPD patients newly initiating 
ICS/LABA combination therapy with budesonide/ 
formoterol (BFC) or fluticasone/salmeterol (FSC) in 
a managed care system reported that, no difference 
was observed in rates of health care utilization 
among BFC or FSC users. However, COPD patients 
initiating BFC treatment incurred lower average 
COPD-related and all-cause costs versus FSC 
initiators, which was driven by cumulative 
differences in inpatient, outpatient, and pharmacy 
costs (Davis et al, 2016). 
Other factors were found to influence patients’ 
decision to use the inhalation therapy one of which is 
actual and perceived efficacy and safety of the 
inhalation therapy (Barta et al., 2002; Boyter and 
Carter, 2005; George et al., 2005; Cecere et al., 2012; 
Huetsch et al., 2012; Khdour et al., 2012). Others 
include: socio-demographic factors, including age 
(Mehuys et al., 2010; Agh et al., 2011; Cecere et al., 
2012; Huetsch et al., 2012; Trivedi et al., 2012), 
educational level (Cecere et al., 2012), and ethnicity 
(Cecere et al., 2012), in addition to the complexity of 
drug regimen (George et al., 2006; Mehuys et al., 
2010; Agh et al., 2011; Cecere et al., 2012). All these 
factors were found to have an influence on patients’ 
decisions on not to use the inhalation therapy, which 
might put patients with COPD at risk of treatment 
failures. 
Patients’ beliefs and experiences regarding the efficacy and 
safety of inhaled therapy  
Only few studies have examined patients’ 
perceptions about the efficacy and safety of inhaled 
therapy among COPD patients (Barta et al., 2002; 
George et al., 2005; Boyter and Carter, 2005; Cecere et 
al., 2012 ; Huetsch et al., 2012 ; Khdour et al., 2012). 
Among these studies the use of inhalation therapy 
was highly supported especially by participants who 
reported high adherence rates (Barta et al., 2002; 
Cecere et al., 2012; Khdour et al., 2012). The benefit 
was seen in the immediate relief of COPD symptoms 
and decreased hospital admissions (Melani et al., 
2001; Barta et al., 2002). However, in some of these 
studies patients were less confidence in LABS and 
ICS received which had a negative effect on 
medication use (Huetsch et al., 2012).  
In Huetsch et al.’s, study (2012), it was suspected that 
the higher adherence to ipratropium bromide (IP), 
but not to LABA and ICS, may be related to the 
perceived immediate benefit of IP on symptom relief. 
In addition, although patients were typically 
instructed to use IP at regular intervals, patients 
might instead be using IP as a rescue medication 
whereas clear instructions were typically given that 
neither ICS nor LABA should be used in this manner 
(Huetsch et al., 2012). It is hypothesised that, because 
LABA and ICS have no immediate effect on 
symptoms (Cecere et al., 2012; Huetsch et al., 2012; 
Trivedi et al., 2012). In addition, each medication 
class has a unique side effect profile (Huetsch et al., 
2012). For instance, inhaled LABAs have been 
reported to cause tremors (Barta et al., 2002; Boyter 
and Carter, 2005), dry mouth (Barta et al., 2002; 
Boyter and Carter, 2005), and less frequently 
palpitations (Barta et al., 2002). These side effects 
were reasonable to expect that a patient who 
experiences such a side effect to these mediations 
may preferentially adhere to their other inhalers. 
These concerns or experiencing an actual side effect 
from treatment affected patients’ decisions to use the 
inhaled medication as suggested which may lead to 
treatment failures.  
Problems encountered with the use of inhalation devices in 
regards to the operation and inhalation techniques 
Problems were reported with the inhalation 
techniques when operating the inhalers including: 
pMDIs alone or with large-volume spacers (Ho et al., 
2004), DPIs alone including Accuhaler, Turbohaler, 
Handihaler, and Aerolizer (Wilson et al., 2007), or a 
combination of both pMDIs and DPIs (Hesselink et 
al., 2001; Sestini et al., 2006; Khassawneh et al., 2008; 
De Moraes Souza et al., 2009; Rootmensen et al., 2010; 
Hämmerlein et al., 2011; Melani et al., 2011). In all 
studies, COPD patients were found to be using a 
combination of inhalation devices either from the 
same class (different types of dry powder inhalers 
together or different types of pMDIs in combination) 
(Ho et al., 2004; Wilson et al., 2007), or different 
classes including pMDIs and DPIs (Lenney et al.,  
2000 ; Hesselink et al., 2001; Sestini et al., 2006; 
Khassawneh et al., 2008; De Moraes Souza et al., 2009; 
Rootmensen et al., 2010; Hämmerlein et al., 2011; 
Melani et al., 2011). These devices were commonly 
used to deliver mainly the following: salbutamol by 
pMDIs, salmeterol/fluticasone by Accuhalers; 
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terbutaline and formoterol/budesonide by 
Turbohalers; salbutamol, salmeterol/beclometasone 
or fluticasone by Accuhaler; formoterol by Aerolizer 
and tiotropium by Handihaler. 
Participants using pMDIs and DPIs were found to 
handle their inhalation devices erroneously as the 
percentage of participants with COPD who made at 
least one deviation from the recommended technique 
ranged from 2.9% (De Moraes Souza et al., 2009) to 
94.2% (Ho et al., 2004). The percentage of COPD 
participants who made at least one deviation from 
the recommended inhalation technique was greater 
among pMDIs users than DPIs users (Lenney et al., 
2000; Hesselink et al., 2001; Khassawneh et al., 2008; 
De Moraes Souza et al., 2009; Rootmensen et al., 
2010). However, different studies by Melani et al 
(2011) and Ho et al (2004) reported that pMDIs were 
correctly used by most patients, especially with large 
volume spacers (Ho et al., 2004; Melani et al., 2011). 
Three studies found no significant difference 
between the pMDIs and DPIs; therefore, they were 
handled similarly by all patients (Lenney et al.,  2000; 
Ho et al., 2004; Hämmerlein et al., 2011). Examining 
the inhalation technique among COPD patients with 
different devices is important, to detect whether 
users are using them effectively or not, as suboptimal 
techniques affect the drug delivery and moderate the 
efficacy of the therapy and are a cause of treatment 
failures and poor clinical outcomes (Rootmensen et 
al., 2010). 
For the pMDIs, the steps concerning shaking inhaler 
(the canister) well before use and actuating while 
inhaling deeply and slowly were the most frequently 
performed incorrectly, with the inhaler not being 
shaken (N=7) (Hesselink et al., 2001 ; Molimard et al.,  
2003 ; Ho et al., 2004 Sestini et al., 2006 Khassawneh 
et al., 2008 Rootmensen et al., 2010 ; Melani et al., 
2011), or the device being fired before start of 
inhalation or after end of inhalation (N=4) (Ho et al., 
2004; Sestini et al., 2006; Khassawneh et al., 2008; 
Rootmensen et al., 2010). For the DPIs, the most 
common errors were in not exhaling away from the 
inhaler before inhalation or exhaling into the 
mouthpiece (N=5) (Molimard et al., 2003 ; Sestini et 
al., 2006 ; Rootmensen et al., 2010 Hämmerlein et al., 
2011 Melani et al., 2011), and no/short holding of 
breath for less than five seconds (N=4) (Molimard et 
al., 2003; Sestini et al., 2006; Rootmensen et al., 2010; 
Melani et al., 2011). 
Further studies of inhalation technique in DPIs 
(Accuhaler, Turbohaler, Aerolizer, Handihaler and 
Diskhaler), reported that the percentage of COPD 
participants who made at least one deviation from 
the recommended inhalation technique when using 
DPIs was more when using single-dose DPIs such as 
Handihaler (Wilson et al., 2007), and Aerolizer 
(Wilson et al., 2007; Khassawneh et al., 2008; De 
Moraes Souza et al., 2009) than when using the 
multiple-dose DPIs such as Turbohaler and 
Accuhaler. These findings were contradicted by two 
other studies documenting that the essential errors 
which compromise treatment efficacy were made 
more among Turbohaler users than other DPI users 
using Aerolizer and Accuhaler (Molimard et al., 
2003), or Handihaler and Accuhaler (Melani et al., 
2011). 
Checklists used for the inhalation technique assessment in 
previous studies  
Most previous studies have adopted checklists for 
the inhalation technique assessment among COPD 
patients. They have been based on previously 
published checklists or by using checklists given by 
pharmaceutical companies or medical leaflets 
(Lenney et al., 2000; Molimard et al., 2003; Sestini et 
al., 2006; Wilson et al., 2007), or previously published 
criteria by previous raters (Ho et al., 2004; De Moraes 
Souza et al., 2009; Rootmensen et al., 2010; Melani et 
al., 2011). Two other studies developed their own 
checklists, based on information from the drug 
information centre of the German Association of 
Pharmacists (Hämmerlein et al., 2011), or the Dutch 
Asthma Foundation (Hesselink et al., 2001). 
Definition of inadequate inhalation technique 
The majority of studies defined essential steps for 
optimal delivery of the active drug into the lungs for 
each device. When one or more deviations were 
made regarding these essential steps, the inhalation 
technique was defined as inadequate or incorrect, 
potentially resulting in suboptimal drug delivery to 
the lungs (Lenney et al., 2000; Hesselink et al., 2001; 
Molimard et al., 2003; Ho et al., 2004; Sestini et al., 
2006; Wilson et al., 2007; Khassawneh et al., 2008 
Rootmensen et al., 2010; Melani et al., 2011). Despite 
the importance of defining the adequate inhalation 
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technique, past studies have not used validated 
instruments when assessing the inhalation 
technique. Only one study used a validated scoring 
method, which involved viewing and assessing a 
video-recorded inhalation demonstration by 
participants using device-specific checklists and 
mutually agreed scoring rules by raters (Rootmensen 
et al., 2010). However, to maximise the accuracy of 
the findings, some studies included more than one 
rater in the assessment process (Lenney et al.,  2000; 
Molimard et al., 2003; Sestini et al., 2006; Wilson et 
al., 2007; Rootmensen et al., 2010; Melani et al., 2011), 
whilst others included only one rater (Ho et al., 2004; 
De Moraes Souza et al., 2009; Hämmerlein et al., 
2011). 
Many past studies have assessed inhalation 
technique among patients with a number of lung 
diseases including asthma and COPD (Hesselink et 
al., 2001; Ho et al., 2004; De Moraes Souza et al., 2009 
; Rootmensen et al., 2010 ; Hämmerlein et al., 2011; 
Melani et al., 2011). Two of those have shown that 
COPD patients made or were more likely to make 
more deviations from the recommended inhalation 
technique when using their inhalers than those with 
asthma (De Moraes Souza et al., 2009; Melani et al., 
2011). Some other past studies have included only 
one class of device in the assessment process, such as 
pMDIs only (Ho et al., 2004), or DPIs only (Wilson et 
al., 2007). No previous study assessed the inhalation 
technique using all three classes of inhalation devices 
to examine what device was associated with more 
errors or deviations when assessing the technique. 
Therefore, there is a need for more studies to examine 
how patients practically use a combination of 
inhalation devices and what are the frequency and 
range of problems experienced by patients that may 
lead to suboptimal use or treatment failure. 
Discussion 
With regards to the findings reported in these studies 
on medication use, careful attention must be paid 
before coming to such a conclusion because of the 
wide discrepancy reported in the rates of non-
adherence to COPD medication, which ranges from 
29.5% (Khdour et al., 2012) to 80% (Trivedi et al., 
2012). This variation can be explained by the 
dissimilarities in COPD population (e.g. age, disease 
severity, smoking history, etc.), the differences in 
adherence/non-adherence definition and the 
variation of methods employed. The results are also 
limited by the duration of some studies, which 
ranged from two weeks (Boyter and Carter, 2005) to 
12 months (Mehuys et al., 2010).  
Although a number of instruments and methods 
have been used to measure adherence, there was no 
gold standard method for measuring medicine 
taking due to the advantages and disadvantages of 
each method. For example, the easiest and most 
feasible way for most settings to measure medicine 
taking is to collect information from the patients 
themselves through questionnaires which were used 
in most reported studies (Melani et al., 2001; George 
et al., 2005; Agh et al., 2011; Khdour et al., 2012). 
However, a direct self-report method such as a 
questionnaire may overestimate adherence and may 
be subject to memory biases. In two studies 
adherence was not assessed using validated tools 
(e.g. surveys); in these studies when optimal 
adherence was noted by the authors, this might be 
biased as patients were received instructions prior to 
their adherence assessments (Barta et al., 2002; Boyter 
and Carter, 2005). 
The use of inhalation therapy was found to be 
influenced by patients’ decisions, which in turn were 
guided by many factors. However, the most 
frequently reported factor was actual and perceived 
efficacy and safety of the inhalation therapy. Despite 
the perceived effectiveness reported by most patients 
using inhalation therapy in studies that examined 
patients’ believes about inhaled therapy (Melani et 
al., 2001 Barta et al., 2002; Khdour et al., 2012), these 
studies did not mention whether their outcome was 
measured by means of validated questionnaires, 
except for one study which used a validated 
questionnaire (e.g. Health Belief Model 
questionnaire) (Khdour et al., 2012). Two studies 
described the instruments used to assess the 
subjective benefits, however, no details were gives 
about their validity and reliability (Melani et al., 2001 
Barta et al., 2002). In one of these two studies no 
measure of objective validity was obtained for the 
responses, and no information was collected on non-
respondents (Melani et al., 2001). 
There were some contradictory results among these 
studies examining the factors affecting the 
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medication use. For example, in four studies, it was 
found that, as complexity of the medical regimen 
increases (e.g. the number of medications, frequency 
of dosage, etc.), medicine taking decreases (George et 
al., 2005; Mehuys et al., 2010; Agh et al., 2011; Cecere 
et al., 2012), whereas the same factor was not a 
significant predictor of non-adherence in George et 
al.’s, study (2005) (George et al., 2005). Other studies 
have shown that disease severity or the decline in the 
FEV1% may be either not (Agh et al., 2011), or 
negatively related to medicine taking (Cecere et al., 
2012; Khdour et al., 2012).  Others have shown that 
adherence is related to age: some authors found that, 
among adults, older age had a positive association 
with medicine taking (Mehuys et al., 2010; Agh et al., 
2011), while others found that older age had a 
negative association with medicine taking due to risk 
of memory loss and cognitive impairment, which are 
associated with age and may adversely affect 
adherence (Cecere et al., 2012; Huetsch et al., 2012; 
Trivedi et al., 2012). 
Studies which examined how patients operate their 
inhalers were also at risk of selection bias as some 
studies included only one class of device in the 
assessment process, such as pMDIs only (Ho et al., 
2004) or DPIs only (Wilson et al., 2007). No previous 
study assessed the inhalation technique using all 
three classes of inhalation devices to examine what 
device was associated with more errors or deviations 
when assessing the technique. In addition, the 
inhalation technique, breathing pattern and drug 
administration were not examined in previous 
studies. Among the devices examined in previous 
studies including pMDIs and DPIs, incorrect use was 
very common among patients with COPD and was 
more frequently associated with the use of pMDIs 
than DPIs. 
The reviewed studies on the medication use had 
several limitations which might affect explorating 
findings from these studies to other population or 
settings. One of the limitation was the inclusion 
criteria which was a particular issue in the reviewed 
studies; some studies included patients who were 
carefully selected and received instructions prior to 
the study enrolment (Barta et al., 2002; Boyter and 
Carter, 2005). A minimum duration of use, for a six 
months or more was a part of the inclusion criteria in 
some studies (Melani et al., 2011; Huetsch et al., 
2012). Other studies excluded any COPD patient who 
had a history of asthma or other respiratory disease, 
or had a heart failure, moderate to severe learning 
difficulties or severe mobility problems or had 
attended a pulmonary rehabilitation programme 
(Agh et al., 2011; Khdour et al., 2012; Trivedi et al., 
2012). In one study selection was biased and only 
patients with stable COPD (defined as “no 
prescription for systemic corticosteroids”) and a 
smoking history of at least 10 pack-years were 
included in the study (Mehuys et al., 2010). Another 
limitation is that this review was a part of a big study 
conducted in four years among patients with COPD 
who are using only a combination of classic old 
devices in their homes including pMDIs, DPIs 
(Turbuhaler, Handihaler, Accuhaler, Diskhaler, 
Aerolizer and Clickhaler) and nebulisers. The newest 
inhaler products to the market such as soft mist 
inhalers (e.g. Respimat®) were not part of this study 
because patients were not using them at home. 
Therefore, they were not included in the review. 
However, future work can be done to compare the 
new devices with the old ones and see how patients 
are using them and whether they prefer the old 
classic devices or the new ones. In addition, searches 
were limited to the period from 2000 to 2013 and all 
other studies conducted from 2014 and to date is the 
subject to future works. 
CONCLUSION 
Treatment failures were a major concern for COPD 
patients due to suboptimal use of medication and a 
wide range of problems with inhaler handling 
among COPD patients which were revealed by this 
review. Therefore, there is a need for studies that 
examine how patients make decisions regarding the 
use of inhalation therapies especially when a 
combination of inhalation devices is used at home, 
and how those decisions and difficulties may 
contribute to suboptimal outcomes and treatment 
failures. 
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